

REMARKS

Claims 16, 18-29 and 43, 45-55, 79 and 80, and new claims 81-84 are pending in this application.

New claims 81-84 have been added to recite specific features of the present invention. Support for the claim amendment can be found in the original claims 17 and 44, which have been canceled without prejudice, and in the specification at, *e.g.*, page 10, line 6 to page 11, line 5. Since no new matter has been introduced by the amendment, Applicants respectfully request their entry into the records of the present application.


Applicants respectfully request that the Examiner consider the new claims and Applicants' response filed on April 2, 2002. Applicants further submit that pending claims 16, 18-29, 43, 45-55, and 79-84 are in condition for allowance.

No fee is believed to be due for this submission. Should any additional fee be required, however, please charge such fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

Date

May 2, 2002


Beibing Gary Zhang

47,331

(Reg. No.)

For: Anthony M. Insogna (Reg. No. 35,203)

PENNIE & EDMONDS LLP
1667 K Street, N.W.
Washington, D.C. 20006
(202) 496-4400

Enclosures

APPENDIX A

New claims 81-84 are added as follows:

81. (New) The method of claim 16, wherein the method avoids the concomitant liability of adverse effects associated with the administration of racemic bupropion.

82. (New) The method of claim 16, wherein the amount is sufficient to alleviate nicotine addiction, but insufficient to cause adverse effects associated with administration of racemic bupropion.

83. (New) The method of claim 43, wherein the method avoids the concomitant liability of adverse effects associated with the administration of racemic bupropion.

84. (New) The method of claim 43, wherein the amount is sufficient to achieve smoking cessation, but insufficient to cause adverse effects associated with administration of racemic bupropion.

APPENDIX B

The pending claims, after entry of the present amendment, are as follows:

16. A method for treating nicotine addiction in a human suffering from nicotine addiction, which comprises administering to said human a therapeutically effective amount of (-)-bupropion, or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer.
18. The method of claim 16 wherein (-)-bupropion is administered intravenously, transdermally, or orally.
19. The method of claim 18 wherein (-)-bupropion is administered orally as a tablet or a capsule.
20. The method of claim 18 wherein the amount administered is from about 10 mg to about 750 mg.
21. The method of claim 19 wherein the amount administered is from about 50 mg to about 600 mg.
22. The method of claim 20 wherein the amount administered is from about 60 mg to about 450 mg.
23. The method of claim 16 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is greater than approximately 90 % by weight of the total amount of bupropion.
24. The method of claim 16 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is 99 % or more by weight of the total amount of bupropion.
25. The method of claim 16 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer, is administered together with a pharmaceutically acceptable carrier.
26. The method according to claim 16 wherein (-)-bupropion is administered as the hydrochloride salt.
27. The method of claim 16 wherein (-)-bupropion is administered in a sustained or controlled release formulation.

28. The method of claim 16 wherein said nicotine addiction is an addiction to smoking, or chewing tobacco.

29. The method of claim 16 wherein said administration is made one to four times a day.

43. A method for aiding smoking cessation in a human who smokes, which comprises administering to said human a therapeutically effective amount of (-)-bupropion, or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer.

45. The method of claim 43 wherein (-)-bupropion is administered intravenously, transdermally, or orally.

46. The method of claim 45 wherein (-)-bupropion is administered orally as a tablet or a capsule.

47. The method of claim 43 wherein the amount administered is from about 10 mg to about 750 mg.

48. The method of claim 47 wherein the amount administered is from about 50 mg to about 600 mg.

49. The method of claim 48 wherein the amount administered is from about 60 mg to about 450 mg.

50. The method of claim 43 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is greater than approximately 90 % by weight of the total amount of bupropion.

51. The method of claim 43 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof is 99 % or more by weight of the total amount of bupropion.

52. The method of claim 43 wherein the amount of (-)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (+)-stereoisomer is administered together with a pharmaceutically acceptable carrier.

53. The method according to claim 43 wherein (-)-bupropion is administered as the hydrochloride salt.

54. The method of claim 43 wherein (-)-bupropion is administered in a sustained or controlled release formulation.

55. The method according to claim 43, wherein said administration is made one to four times per day.

79. The method of claim 45, wherein the (-)-bupropion is administered by bolus injection.

80. The method of claim 45, wherein the (-)-bupropion is administered intrathecally.

81. (New) The method of claim 16, wherein the method avoids the concomitant liability of adverse effects associated with the administration of racemic bupropion.

82. (New) The method of claim 16, wherein the amount is sufficient to alleviate nicotine addiction, but insufficient to cause adverse effects associated with administration of racemic bupropion.

83. (New) The method of claim 43, wherein the method avoids the concomitant liability of adverse effects associated with the administration of racemic bupropion.

84. (New) The method of claim 43, wherein the amount is sufficient to achieve smoking cessation, but insufficient to cause adverse effects associated with administration of racemic bupropion.